Synthesis of rearranged indole diterpenes of the paxilline type

Covering: up to 2021 Rearranged indole diterpenes of the paxilline type comprise a large group of fungal metabolites that possess diverse structural features and potentially useful biological effects. The unique indoloterpenoid motif, which is common to all congeners, was first confirmed by crystall...

Full description

Saved in:
Bibliographic Details
Published inNatural product reports Vol. 39; no. 5; pp. 946 - 968
Main Authors Schatz, Devon J, Kuenstner, Eric J, George, David T, Pronin, Sergey V
Format Journal Article
LanguageEnglish
Published England Royal Society of Chemistry 26.05.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Covering: up to 2021 Rearranged indole diterpenes of the paxilline type comprise a large group of fungal metabolites that possess diverse structural features and potentially useful biological effects. The unique indoloterpenoid motif, which is common to all congeners, was first confirmed by crystallographic studies of paxilline. This family of natural products has fascinated organic chemists for the past four decades and has inspired numerous syntheses and synthetic approaches. The present review highlights efforts that have laid the foundation and introduced new directions to this field of natural product synthesis. The introduction includes a summary of biosynthetic considerations and biological activities, the main body of the manuscript provides a detailed discussion of selected syntheses, and the review concludes with a brief outlook on the future of the field. Paxilline indole diterpenes have fascinated chemists for the past several decades. This review highlights the diversity of strategies and tactics that have been employed in the corresponding area of organic synthesis, from inception to the present.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
Current address: Gilead Sciences, Foster City, CA 94404.
Current address: Bristol Myers Squibb, New Brunswick, NJ 08901.
Current address: Entasis Therapeutics, Waltham, MA 02451.
These authors contributed equally.
The manuscript was written through contributions of all authors.
Author contributions
ISSN:0265-0568
1460-4752
1460-4752
DOI:10.1039/d1np00062d